SUBTLE Study enrolls first participants
In an earlier blog post from August 2024, the Vanderbilt TB Center announced that it had received $2.3 million in project funding from CRDF Global,
Drs. Robert Watson and Kristin Patrick join VTC
The Vanderbilt Tuberculosis Center is fortunate be joined by Drs. Robert "Robbie" Watson and Kristin Patrick. They join us from Texas A&M, bringing with them considerable expertise and stellar labs focused on basic science and macrophage innate immune response is regulated during bacterial infection Here are some details regarding their labs:
VTC Welcomes RICC Leadership Team to Nashville for in-person meeting
The RePORT International leadership team gathered in Nashville, Tennessee from 4-5 November 2024 for an in-person meeting. The group reviewed the RICC "Report Card" which assessed the progress made on the consortium's strategic goals for the past year, identified areas for improvement, and discussed big picture goals going forward.
VUMC investigators attend RePORT-International Annual Meeting
VUMC investigators and staff, Timothy Sterling, Stephany Duda, G
Dr. Dooley’s TB research receives MERIT Award from the NIH
Kelly Dooley, MD, PhD, MPH, Addison B. Scoville Jr. Professor of Medicine and director of the Division of Infectious Diseases at Vanderbilt University Medical Center, has received a MERIT Award (Method to Extend Research in Time Award) from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
VTC to lead a $2.3 million study on subclinical TB
The Vanderbilt TB Center will lead a two-year, $2.3 million project funded by CRDF Global, to conduct research on the prevalence and incidence of subclinical tuberculosis(TB) in close contacts and evaluate novel biomarkers and diagnostic tests for subclinical TB. The true prevalence and incidence of subclinical TB in close TB contacts is unclear, and the optimal diagnostic method for subclinical TB is unknown.
NIH Awards UM1 Funding to Establish PReDicTR Consortium
Rada Savic, PhD and colleagues Eric Nuermberger, MD (JHU), Kelly Dooley, MD, PhD, MPH (Vanderbilt), and Dirk Schnappinger, PhD (WCM) have been awarded a five-year $30.8M, UM1 cooperative agreement award from NIAID/NIH to establish a consortium of tuberculosis preclinical and clinical experts to research the most effective treatment options for future clinical testing, called the Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium. PReDicTR will establish a mu
VTC Hosts LTBI R01 Meeting
The Vanderbilt Tuberculosis Center recently hosted a meeting of researchers involved in our LTBI R01 project “Immunogenetic predictors of active and incipient TB in HIV-negative and -positive close TB contacts” (NIH R01AI147765). The event, which took place between March 21st and 22nd, and included presentations about ongoing research and data findings, working group sessions, and breakout meetings.
RePORT-Brazil Investigators at CROI 2024
The 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver was attended by investigators from RePORT-Brazil, including presentations on recent findings and articles. Poster Presentations:Dr. Gustavo Amorim, PhD - "Estimating Optimal Anti-TB Drug Concentrations in a Prospective, Observational Cohort in Brazil"Dr. Felipe Ridolfi, PhD, MD - “Pharmacogenetic Associations With HIV-1 Virologic Suppression Among Patients with TB/HIV in Brazil”
RePORT-Brazil in the Spotlight - CID Article
A recently publication in the journal Clinical Infectious Diseases is catching attention. The Xpert® MTB/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort was published by the RePORT-Brazil consortium, with authorship being led by the team at the Fundação de Medicina Tropical in Manaus, Amazonas, Brazil.
TBTC Launches CRUSH-TB trial
CDC’s Tuberculosis Trials Consortium (TBTC) has recently launched the CRUSH-TB trial, which aims to identify new combinations of drugs to shorten treatment of active TB disease. Kelly Dooley, MD, PhD, MPH, Director, Division of Infectious Diseases, is a Protocol Chair for this new study.
Read more from CDC’s TB Notes newsletter: